openPR Logo
Press release

Radiation-Induced Myelosuppression Treatment Market Opportunity Analysis by 2028 | Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC, Amgen Inc., Mylan NV, Novartis AG, and Partner Therapeutics

01-30-2019 12:55 PM CET | Health & Medicine

Press release from: Future Market Insights

Radiation-Induced Myelosuppression Treatment Market

Rapidly improving healthcare infrastructure and reimbursement scenario has been a major booster for the healthcare industry in developing regional markets. With incessantly increasing number of cancer cases, it is more likely that the subsequent demand for a wide range of treatments adopted to treat cancer patients would also remain on a constant rise over the course of coming years.

Radiation therapy has been a significant part of cancer treatment and the consistently high success rate associated with radiotherapy is projected to further push demand for radiation-induced myelosuppression treatment worldwide.

A new market research study on global radiation-induced myelosuppression treatment forecasts steady growth for the market in the next few years. Future Market Insights projects a moderate, just-under 4% yearly growth outlook, in 2019 and ahead.

Nutropenia is foreseen to generate maximum demand for radiation-induced myelosuppression treatment, whereas injectables are identified to hold a substantial share in the total market value, based on the route of administration of radiation-induced myelosuppression treatment. Thrombocytopenia and anemia are likely to present lucrative opporunities for radiation-induced myelosuppression treatment providers.

Get Sample Copy of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-8116

Report tracks key factors driving revenue growth of the market -

Increasing prevalence of cancers

Early diagnosis, promising improved chances of positive outcomes

Fostering R&D funds supporting cancer research

Strong product pipeline

Bolstering adoption of chemo-radiotherapy in cancer treatment

In the backdrop of patent expiry, a majority of market leaders are shifting their focus to the expansion of product pipeline of a wide range of innovative formulations, likely to shape the radiation-induced myelosuppression treatment landscape.

Myelo001 by Myelo Therapeutics GmbH recently received an FDA approval as an orphan drug to be used in the ARS (acute radiation syndrome) treatment.

Mylan NV and Pfizer Inc. also reveived FDA approvals for their recently launched biosimilars - Epogen and Neupogen, and Neulasta respectively.

Patent expiry of originator biologics formulations is creating investment opportunities in biosimilars production – for the operators in radiation-induced myelosuppression treatment landscape. As there is a considerable cost difference of around 20% between originator biologics and biosimilars, patients are inclined more towards an economical means of treatment, thereby fueling the scope of penetration of radiation-induced myelosuppression treatment in coming years.

Backed by a majority of established players housing strong bases across North America, especially the US, the report indicates a steady growth outlook for the radiation-induced myelosuppression treatment market in the region. North America will reportedly continue to account for over 65% share in the global market value.

New product launches currently mark the top developmental strategy adopted by leading companies competing in the radiation-induced myelosuppression treatment market. A majority of key players are also identified to focus on enhancing their geographical foothold in global radiation-induced myelosuppression treatment landscape. The report in a distinct section covers some of the key competitors operating in radiation-induced myelosuppression treatment marketplace, emphasizing their financial as well as strategic profiles in depth.

A few of the profiled companies include Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC (Johnson & Johnson), Amgen Inc., Mylan NV, Teva Pharmaceutical Industries Ltd., Novartis AG, and Partner Therapeutics, Inc.

Request Customized Copy of Report @ https://www.futuremarketinsights.com/customization-available/rep-gb-8116

In the highly consolidated competitive landscape of global radiation-induced myelosuppression treatment, the three top ranking companies, i.e. Janssen Pharmaceutical NV, Amgen Inc., and Teva Pharmaceutical Industries Ltd. dominate in terms of market value. These players continue to hold winning revenue shares in the radiation-induced myelosuppression treatment owing to strong global presence and a considerable number of new drug approvals. Established companies are entering strategic partnerships and collaborations with regional leaders, in an effort to achieve better penetration into regional markets.

About Us

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Contact Us

U.S. Office

616 Corporate Way, Suite 2-9018,

Valley Cottage, NY 10989,

United States

T: +1-347-918-3531

F: +1-845-579-5705

Email: sales@futuremarketinsights.com

Web: https://www.futuremarketinsights.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Radiation-Induced Myelosuppression Treatment Market Opportunity Analysis by 2028 | Pfizer Inc., Janssen Pharmaceutical NV, Janssen Global Services, LLC, Amgen Inc., Mylan NV, Novartis AG, and Partner Therapeutics here

News-ID: 1546173 • Views:

More Releases from Future Market Insights

Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
The Anesthesia Equipment Market is witnessing robust growth, with its value estimated at USD 9.3 billion in 2025 and projected to nearly double to USD 18.2 billion by 2035. This growth trajectory represents a compound annual growth rate of 7.0%, driven by increasing surgical volumes, rising prevalence of chronic respiratory and cardiovascular disorders, and ongoing expansion of healthcare infrastructure. The market is undergoing transformative change, as both established manufacturers and
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
The intravascular ultrasound (IVUS) systems market is on track to record consistent growth over the next decade. Valued at USD 893.7 million in 2025, the market is expected to expand to USD 1455.7 million by 2035, reflecting a compound annual growth rate of 5.0%. With cardiovascular disease remaining one of the leading causes of mortality globally, the demand for advanced intravascular imaging technologies is escalating. IVUS systems, which provide real-time
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
The global Electric Power Sports Market is on a fast track to transformation, as consumers, manufacturers, and policymakers align on one powerful goal: sustainable, high-performance recreational experiences. Valued at USD 10.3 billion in 2025, the market is projected to expand to USD 18.5 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.0%. This momentum is set to generate an absolute dollar opportunity of USD 8.2 billion over
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovation and Consumer Demand Drive Growth
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovatio …
The global hair straightener market is entering a transformative growth phase, as industry leaders and emerging brands alike innovate to meet rising consumer demand for advanced hair styling solutions. Valued at USD 7.1 billion in 2025, the market is projected to reach USD 12.4 billion by 2035, registering a compound annual growth rate (CAGR) of 5.7% over the forecast period. Between 2025 and 2030, the market is set to rise steadily

All 5 Releases


More Releases for Myelo

Chemotherapy Induced Neutropenia Market Predicted to See Upsurge Through 2032, H …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia
Chemotherapy Induced Neutropenia Market Forecasted to Surge in Coming Years, 202 …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia
Chemotherapy Induced Neutropenia Market is Expected to Expand at a Healthy Growt …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia
Chemotherapy Induced Neutropenia Market Report 2032: Epidemiology Data, Pipeline …
DelveInsight's "Chemotherapy Induced Neutropenia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chemotherapy Induced Neutropenia, historical and forecasted epidemiology as well as the Chemotherapy Induced Neutropenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. To Know in detail about the Chemotherapy Induced Neutropenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chemotherapy Induced Neutropenia
Neutropenia Treatment Market to see Huge Growth by 2026 | Mylan, BeyondSpring, M …
Stay up-to-date and exploit latest trends of Neutropenia Treatment Market with latest edition released by AMA. Neutropenia Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Neutropenia Treatment industry with an attention on the Global market. The report gives key insights available status of the Neutropenia Treatment producers and is an important wellspring of direction and course for organizations and people
Chemotherapy Induced Thrombocytopenia Drugs Market In-Depth Analysis Of Competit …
Complete study of the global Chemotherapy Induced Thrombocytopenia Drugs market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global Chemotherapy Induced Thrombocytopenia Drugs industry. Research techniques like PESTLE and Porter's Five Forces analysis have been deployed by the